Overview
Scanome develops AI tools for digital pathology, image analysis, and diagnostics, including cervical cancer diagnosis. Its offerings include the ScanAI platform, training for cytologists and pathology professionals, and custom AI solutions for medicine. It also provides the LIS NG system for pathology laboratory workflows and molecular profiling using next-generation sequencing and bioinformatics.
Financials
The financial statement for 2025 has not yet been filed with the Financial Document Repository (past deadline).
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2024.
Results vs industry
News
AI in Cervical Cytology: What the Evidence Shows, and What It Doesn't Yet
A new open-access narrative review in Diagnostics (MDPI) maps how artificial intelligence is being applied across cervical cancer screening, triage, and diagnosis — and is candid about the limitations that still stand between promising results and routine clinical use.
Cervical Cancer Learning Platform Release
Scanome announces the launch of its cutting-edge educational platform designed specifically for cytologists and pathology professionals, integrating with ScanAI to redefine cervical cancer diagnosis training.
ScanAI Digital Pathology Platform Launch
Scanome Announces the Launch of ScanAI - A Revolutionary AI-Powered Digital Pathology Solution for Cervical Cancer Diagnosis
Industry
Bank accounts
Registered as a VAT taxpayer on 2023-06-30. Active
54 1050 1012 1000 0090 3295 3912- 76 1050 1012 1000 0090 3295 3904
- 32 1050 1012 1000 0090 3295 3920
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
No public aid cases recorded in the last 10 years.
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
Each member of the management board is authorized to make declarations on behalf of the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Piotr Religa (54) | 50 | $1,350.62 | 50% |
Tomasz Religa (47) | 50 | $1,350.62 | 50% |
Piotr Religa and Tomasz Religa hold a combined 100% – the ownership structure indicates family control.
Beneficial owners
| Person | Rights |
|---|---|
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Digital Pathology Teamsp. z o.o. | $64,552.91 | digitalpathologyteam.com | ||
| Oncocdxsp. z o.o. | $58,823.32 | oncocdx.org | ||
| Medapp Clinical Researchsp. z o.o. | $55,499.75 | medappclinicalresearch.pl | ||
| Biostat Research and Developmentsp. z o.o. | $50,225.77 | biostat.com.pl | ||
| Advanced Diagnostic Equipmentsp. z o.o. | $43,171.56 | adediabetics.pl | ||
| Ai4isp. z o.o. | $41,814.69 | ai4i.pl | ||
| CannamedaiS.A. | $28,203.90 | cannamedai.com | ||
| Data2biologysp. z o.o. | $28,567.58 | data2biology.com | ||
| Medaisp. z o.o. | $22,311.83 | medai.pl | ||
| Liver Aisp. z o.o. | $8,443.59 | liverai.pl |
FAQ
Last updated: 2026-04-21